News Article
Dynavax Announces FDA Approval of HEPLISAV-B™ for Prevention of Hepatitis B in Adults
Posted on November 10, 2017
Blog: National Association of County & City Health Officials (NACCHO)
Dynavax Technologies Corporation announced that the U.S. Food & Drug Administration (FDA) has approved HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. HEPLISAV-B is the first new hepatitis B vaccine in the United States in more than […]